Skip to main content
OpenTrials

Clinical trial condition

Primary Immunodeficiency Diseases

Explore clinical trials studying Primary Immunodeficiency Diseases. Study availability and eligibility vary by location and protocol.

161 public trials 33 recruiting studies
Refine in advanced search Browse all conditions

Primary Immunodeficiency Diseases trial results

Completed

High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)

NCT01313507

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • University of California Irvine Irvine, California, United States
  • Immunoe Research Center Centennial, Colorado, United States
  • Rush Universtity Medical Center Chicago, Illinois, United States
  • Cardinal Glennon Children's Hospital St Louis, Missouri, United States
View Trial Details
Completed

Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases

NCT01963143

Conditions
Blood Protein Disorders, Bruton type agammaglobulinemia, Common Variable Immunodeficiency, +12 more
Locations
  • Arizona Allergy Associates Chandler, Arizona, United States
  • Miller Children's Hospital Long Beach, California, United States
  • Childrens Hospital Los Angeles Los Angeles, California, United States
  • UCLA Medical Center Los Angeles, California, United States
View all 17 locations
View Trial Details
Completed

A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases

NCT01012323

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +2 more
Locations
  • Sudir Gupta, MD Irvine, California, United States
  • Isaac Melamed, MD Centennial, Colorado, United States
  • James Moy, MD Chicago, Illinois, United States
  • William Smits, MD Fort Wayne, Indiana, United States
View Trial Details
Completed

Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects

NCT00634569

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Blood Protein Disorders, +18 more
Locations
  • University of South Florida St. Petersburg, Florida, United States
  • Family Allergy & Asthma Center, PC Atlanta, Georgia, United States
  • Rush University Medical Center Chicago, Illinois, United States
  • The Allergy and Asthma Center Fort Wayne, Indiana, United States
View Trial Details
Completed

Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)

NCT01814800

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • IMMUNOe Health Centers Cenntennial, Colorado, United States
  • Allergy Associates of the Palm Beaches, P.A. North Palm Beach, Florida, United States
  • Family Allergy Center, PC Atlanta, Georgia, United States
  • The South Bend Clinic, LLP South Bend, Indiana, United States
View Trial Details
Completed

A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency

NCT00389324

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • University of California, Irvine Irvine, California, United States
  • UCLA School of Medicine Los Angeles, California, United States
  • Family Allergy & Asthma Center, PC Atlanta, Georgia, United States
  • Allergy, Asthma & Immunology Associates, PC Omaha, Nebraska, United States
View Trial Details
Completed

Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml

NCT01985373

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Jeroen Bosch Ziekenhuis 's-Hertogenbosch, Netherlands
  • UMCG Groningen, Netherlands
  • LUMC Leiden, Netherlands
  • UMC St. Radboud Nijmegen, Netherlands
View Trial Details
Completed

Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency

NCT01465958

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Childrens Hospital Los Angeles Los Angeles, California, United States
  • IMMUNOe International Research Centers Centennial, Colorado, United States
  • Joe DiMaggio Children's Hospital Hollywood, Florida, United States
  • The Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States
View Trial Details

Related conditions